Wells Fargo & Company Codiak Bio Sciences, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.18 - $0.81 $30 - $136	169 Added 103.68%	332 $0
Q4 2022 Feb 13, 2023	SELL	$0.32 - $0.9 $91 - $256	-285 Reduced 63.62%	163 $0
Q3 2022 Nov 14, 2022	SELL	$0.82 - $3.19 $7 - $28	-9 Reduced 1.97%	448 $0
Q2 2022 Aug 12, 2022	SELL	$2.24 - $6.96 $12,091 - $37,570	-5,398 Reduced 92.19%	457 $1,000
Q1 2022 May 16, 2022	SELL	$4.3 - $12.95 $23,146 - $69,709	-5,383 Reduced 47.9%	5,855 $37,000
Q4 2021 Feb 14, 2022	SELL	$10.0 - $16.78 $14,000 - $23,492	-1,400 Reduced 11.08%	11,238 $125,000
Q3 2021 Nov 15, 2021	BUY	$15.58 - $22.88 $191,447 - $281,149	12,288 Added 3510.86%	12,638 $207,000
Q2 2021 Aug 16, 2021	SELL	$11.72 - $26.81 $19,654 - $44,960	-1,677 Reduced 82.73%	350 $6,000
Q1 2021 May 13, 2021	SELL	$13.49 - $31.53 $11,641 - $27,210	-863 Reduced 29.86%	2,027 $31,000
Q4 2020 Feb 09, 2021	BUY	$7.9 - $32.3 $22,831 - $93,346	2,890 New	2,890 $93,000

238K

Ticker CDAK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,995,200
Market Cap $360K
Description
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.